By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Corporation Release: Benefits And Safety Of Pradaxa® (Dabigatran Etexilate Mesylate) Repeatedly Confirmed 7/24/2014 9:12:38 AM
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014 10:38:47 AM
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/8/2014 8:38:37 AM
Boehringer Ingelheim Corporation Submits Applications In Europe For Tiotropium + Olodaterol Respimat® Fixed-Dose Combination In COPD 7/2/2014 10:54:41 AM
U.S. FDA Accepts NDA Filing For Boehringer Ingelheim Corporation's Investigational Nintedanib And Grants Priority Review Designation For The Treatment Of Idiopathic Pulmonary Fibrosis 7/2/2014 8:44:20 AM
Eli Lilly and Company (LLY), Boehringer Ingelheim Corporation Win EU Backing For Copy Of Sanofi (France) (SAN.PA)'s Top Insulin Lantus 6/27/2014 6:15:00 AM
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014 6:54:14 AM
Boehringer Ingelheim Corporation Exits Hepatitis C Field, Pulls Regulatory Filings For Faldaprevir 6/23/2014 7:40:32 AM
Boehringer Ingelheim Corporation Release: New Pradaxa® Clinical Study To Explore Practical Management Of Patients With Atrial Fibrillation Undergoing Ablation 6/20/2014 10:37:12 AM
Boehringer Ingelheim Corporation Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) In NVAF Patients Undergoing Ablation 6/20/2014 6:32:57 AM